Guggenheim 3rd Annual Healthcare Innovation Conference - ENTRADA THERAPEUTICS INC

Explicit Guidance:

• Cash Runway: The company possesses sufficient cash to extend into Q4 2027.
• Dosing Regimens (Anticipated): 44 program is expected to explore doses of 6 mg/kg (Cohort 1), 12 mg/kg (Cohort 2), and potentially 18 mg/kg; 45 program is expected to explore 5 mg/kg (Cohort 1), 10 mg/kg (Cohort 2), and potentially 15 mg/kg.
• Upcoming Milestones: Four significant clinical readouts expected between now and the first half of 2027:
  • Vertex DM1 Phase 1 interim results: Before end of current year.
  • Entrata DMD 44 Cohort 1 (open label, 6 mg/kg): Before end of current year.
  • Entrata DMD 44 Cohort 2 (12 mg/kg): Q1 2027.
  • Entrata DMD 45 Cohort 2 (5 mg/kg, low-dose data disclosure recently followed by Cohort 2): Before end of H1 2027.

Business-Segment Outlook:

• DMD (Exon 44): Anticipates significant dose-response in Cohort 2 compared to Cohort 1, expecting a "hockey stick" inflection in dystrophin production. If efficacy is demonstrated at low doses with minimal dystrophin, it may challenge current field assumptions regarding the dystrophin-functional benefit relationship.
• DMD (Exon 45): Aims to achieve a therapeutic window where 6-week dosing intervals replace weekly 30 mg/kg standard of care (Casimersen), offering a significant convenience advantage.
• DM1 (Vertex Partnership): Expects Vertex to release Phase 1 interim data before year-end; success hinges on observed spliceopathy and functional benefits (e.g., VHAT).
• Platform Expansion: The EEV platform is being utilized across three programs (VX670, 44, 45); management expects continued safety consistency and dose-response optimization across cohorts.
• Functional Benefit: Expectation to see continued functional benefit in open-label studies as drug exposure builds over time, potentially stabilizing or improving disease markers (NSAA, Time to Rise, Poll, 10-meter walk).

Market and Competitive Outlook:

• Dosing Advantage: Projects a major competitive advantage via reduced dosing frequency (every 6 weeks vs. weekly) and lower total annual doses (8–9 vs. 50–52), targeting improved patient adherence and quality of life.
• Differentiation: Anticipates capturing market share by offering a differentiated safety profile (no infusion-related dropouts observed vs. competitor data) and lower drug mass (1/5th the size of Novartis Avidity's drug; 1/6th of Sarepta's Casimersen dose).
• Regulatory Pathway: Believes U.S. FDA approval will rely primarily on statistically significant dystrophin increase (biomarker), while international (non-U.S.) approval will prioritize functional benefit, creating a potential dual-pathway for global launches.
• Market Dynamics: Sees an "unforgiving" market sentiment but believes the unique mechanism of targeting satellite cells allows for functional benefit even at low dystrophin levels, potentially widening the addressable market if the dystrophin-functional correlation is proven non-linear.

Macro / Industry Outlook:

• Regulatory Environment: Expects a bifurcated regulatory view where U.S. agencies prioritize biomarker (dystrophin) for accelerated approval, whereas global agencies prioritize functional endpoints, facilitating a global approval strategy.
• Standard of Care: Acknowledges Casimersen (Sarepta) as the current standard of care generating >$300M in sales, positioning Entorada to challenge this via dosing convenience and safety.
• Competitive Landscape: Notes that competitor programs (e.g., Novartis Avidity's Delozota, Sarepta's Exondys 45) have faced challenges with infusion-related side effects and patient dropouts, positioning Entorada as having a superior safety profile to date.

Strategic Initiatives:

• Clinical Trials: Proceeding with sequential cohort enrollment (Cohort 2 at 12 mg/kg for Exon 44; Cohort 2 at 10 mg/kg for Exon 45) to establish dose-response and safety.
• Capital Strategy: Plans to raise capital in the near future based on data readouts; specifically, positive Vertex data or strong Entorada clinical results are expected to unlock significant financing options and milestones without immediate dilution.
• M&A/Partnerships: The Vertex partnership (upfront $250M, up to $485M milestones) is expected to generate substantial upside as the probability of success increases with upcoming data; these milestone values are excluded from current runway calculations.
• Data Expansion: Plans to include SV95C measurements in expansion cohorts for functional assessment.

Risks and Headwinds to Outlook:

• Dystrophin-Functional Correlation: Risk that the market or regulators may still demand high dystrophin levels for functional benefit, potentially slowing approval or adoption despite observed clinical improvements at low levels.
• Regulatory Uncertainty: The "two-pronged" approach (U.S. biomarker vs. global function) carries execution risk; functional endpoints (Time to Rise, NSAA) are noted as "unfungible" or difficult to measure, potentially complicating data interpretation.
• Safety Liability: While no dropouts have occurred, management acknowledges that the kidney is the primary organ of liability for conventional DMD therapies; any emerging renal toxicity would be a significant risk.
• Blinded Data: Entrada remains blinded to Vertex DM1 data due to a firewall, introducing uncertainty regarding the efficacy expectations for the partnered asset.
• Funding Timing: Management acknowledges a "clock is ticking" regarding capital needs, though they are confident in raising funds post-data release.

Management Tone on the Future:

• Confidence: High confidence in the platform's safety profile (no dropouts) and the potential for a "hockey stick" dose-response in dystrophin production.
• Hedges: Frequent use of qualifiers regarding regulatory endpoints ("hard question," "we'll see," "hypothesis") and uncertainty about the exact dystrophin levels required for profound functional benefit.
• Strategic Pivot: Management is shifting the narrative from purely biomarker-driven value to a combination of convenience, safety, and functional stability, challenging the field's reliance on high dystrophin expression.

Miscellaneous:

• Valuation/Financials: Current runway excludes any potential milestones from the Vertex collaboration, indicating a conservative financial baseline.
• Patient Demographics: DMD 45 trial patients are younger (6–7 years old) with lower baseline dystrophin compared to Exon 44 patients (10–12 years old), creating distinct clinical profiles.
• Drug Mass: Emphasis on the significantly smaller molecular weight of the Entorada conjugate compared to competitors to reduce toxicity in pediatric populations.